Femasys Faces Nasdaq Noncompliance Notice: Stock Price Below $1.00 for 30 Consecutive Business Days

Femasys (FEMY) has received a noncompliance notice from Nasdaq due to its stock price being below $1.00 for 30 consecutive business days. The company has until January 12, 2026, to meet the requirement. Femasys may consider a reverse stock split to regain compliance. The most recent analyst rating is a Buy with a $12.00 price target.

Femasys Inc. (NASDAQ: FEMY), a micro-cap healthcare company, has received a notification from The Nasdaq Stock Market indicating noncompliance with Nasdaq Listing Rule 5550(a)(2). According to the notice, Femasys' common stock had a closing bid price below $1.00 per share for 30 consecutive business days. The rule requires listed companies to maintain a minimum bid price of $1.00 per share for their common stock [1].

The company has been granted a 180-calendar day grace period, ending January 12, 2026, to regain compliance. To achieve compliance, the closing bid price of Femasys' common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the grace period. If Femasys fails to meet this requirement by the end of the applicable compliance period, its common stock may be subject to delisting from Nasdaq [1].

Femasys stated that it intends to monitor the closing bid price of its common stock and may consider options to regain compliance, including a reverse stock split if appropriate. The company noted there is no assurance that it will be able to regain compliance with the minimum bid price requirement or other Nasdaq listing rules [1].

Generation Bio (Nasdaq: GBIO), a biotechnology company, recently implemented a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. This move reduced the number of outstanding shares from approximately 67.3 million to 6.7 million, effectively increasing the per-share price [2].

Femasys faces a potential delisting from Nasdaq due to not meeting the minimum Market Value of Listed Securities requirement, with a deadline to regain compliance by November 17, 2025. The company is actively monitoring its market value and exploring options to meet Nasdaq’s requirements [1].

The most recent analyst rating for Femasys is a Buy with a $12.00 price target, significantly above current levels [1].

References:
[1] https://www.investing.com/news/sec-filings/femasys-receives-nasdaq-notice-for-minimum-bid-price-noncompliance-93CH-4142618
[2] https://www.stocktitan.net/news/GBIO/generation-bio-announces-1-for-10-reverse-stock-qh0adq8j08fk.html